Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.75 | 0.96 | -0.16 | 0.83 |
| FCF Yield | 0.02% | -0.13% | -0.17% | -1.10% |
| EV / EBITDA | -198.78 | 3,946.58 | -202.87 | -217.60 |
| Quality | ||||
| ROIC | 1.69% | -8.61% | -15.65% | 0.05% |
| Gross Margin | 89.54% | 80.10% | 82.65% | 91.94% |
| Cash Conversion Ratio | -0.04 | 0.19 | 0.15 | 2.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 62.06% | 60.29% | 67.87% | 92.25% |
| Free Cash Flow Growth | 117.98% | 22.22% | 82.85% | -54.70% |
| Safety | ||||
| Net Debt / EBITDA | -5.15 | 128.71 | -7.45 | -7.84 |
| Interest Coverage | 0.00 | -1.60 | -2.33 | -0.01 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 0.10 | 0.06 | 0.05 |
| Cash Conversion Cycle | 956.28 | 662.94 | 1,131.73 | 1,364.62 |